ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02915523
Recruitment Status : Active, not recruiting
First Posted : September 27, 2016
Last Update Posted : July 10, 2018
Sponsor:
Collaborators:
Merck KGaA
Pfizer
Information provided by (Responsible Party):
Syndax Pharmaceuticals

Brief Summary:
The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation. Additionally, this study will evaluate the effectiveness of entinostat in combination with avelumab at the determined dose in terms of progression free survival compared to avelumab plus placebo in patients with refractory or recurrent epithelial ovarian cancer.

Condition or disease Intervention/treatment Phase
Epithelial Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer Drug: entinostat Drug: avelumab Drug: Placebo Phase 1 Phase 2

Detailed Description:

The study is comprised of 2 phases: an open-label Safety Lead-in (Phase 1b) followed by an Expansion Phase (Phase 2). The Expansion Phase will evaluate the efficacy and safety of entinostat with avelumab when administered at the Recommended Phase 2 Dose (RP2D) versus avelumab alone in patients with advanced epithelial ovarian cancer in a randomized, double-blind, placebo-controlled setting. In Phase 2, patients will be randomized in a 2:1 ratio to receive avelumab plus entinostat or avelumab plus placebo, respectively.

All patients will be assessed at Screening and at specified times during the conduct of the study using standard clinical and laboratory assessments. Patients will be assessed for response through radiological assessments. Patients will continue receiving their appropriate cycles of study treatment until tumor progression or adverse events (AEs) occur which necessitate discontinuing therapy as determined by the Investigator.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Actual Study Start Date : January 10, 2017
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : March 2021


Arm Intervention/treatment
Active Comparator: Entinostat plus Avelumab
Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with Entinostat administration on D1 and D8 of each cycle at the Maximum tolerated Dose (MTD)/RP2D as determined in the Phase Ib (Dose Determination) part of the study.
Drug: entinostat
An orally available histone deacetylases inhibitor (HDACi).
Other Names:
  • SNDX-275
  • MS-275

Drug: avelumab
A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.
Other Name: MSB0010718C

Placebo Comparator: Placebo plus Avelumab
Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with placebo administered on D1 and D8 of each cycle.
Drug: avelumab
A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.
Other Name: MSB0010718C

Drug: Placebo
A pill containing no active drug ingredient.




Primary Outcome Measures :
  1. Number of Participants taking 5 mg entinostat weekly in combination with avelumab with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 3 months ]
    Phase 1 Dose Determination - Up to 18 patients will be enrolled in this phase of the study which employs a rolling 6 phase 1 design, where six patients must be treated in a dose level and have safety assessed in order to determine the dose-limiting toxicity (DLT) and the MTD and/or RP2D based on entinostat in combination with avelumab

  2. Efficacy of entinostat in combination with avelumab at the RP2D versus avelumab plus placebo [ Time Frame: From date of first dose up to 24 months assessed every 6-8 weeks from screening through the end of study (approximately 24 months) ]
    An evaluation of the efficacy of entinostat in combination with avelumab at the RP2D versus avelumab plus placebo, as determined by the duration of Progression-free Survival (PFS) by RECIST1.1


Secondary Outcome Measures :
  1. Progression-free survival [ Time Frame: From date of first dose through date of progression, expected to be 24 months ]
    Assessed by immune response RECIST (irRECIST). PFS is defined as the number of months from the date of the first dose of study drug to the earliest of documented PD or death due to any cause without prior progression.

  2. Overall Response Rate [Complete Response (CR) or Partial Response (PR)] [ Time Frame: From date of first dose through date of progression, expected to be approximately 12 months ]
    Assessed by RECIST 1.1 and immune response RECIST (irRECIST) every 6-8 weeks

  3. Clinical Benefit Rate [CR or PR, or Stable Disease (SD) for at least 24 weeks] [ Time Frame: From date of first dose through date of progression, expected to be approximately 12 months ]
    Assessed by RECIST 1.1 and irRECIST

  4. Overall Survival [ Time Frame: Approximately 36 months from date of first dose. Overall survival is defined as the number of months from date of first dose to the date of death (due to any cause). ]
  5. Duration of Response (in patients who experience best overall response of CR or PR) [ Time Frame: From date of first dose through date of progression, expected to be approximately 12 months ]
  6. Incidence of treatment-emergent adverse events (TEAES), serious adverse events (SAEs), adverse events resulting in the permanent discontinuation of study drug, and deaths [ Time Frame: 24 months ]
  7. Change from baseline in laboratory assessments [ Time Frame: 24 months ]
  8. Time to Response (in patients who experience best overall response of CR or PR) [ Time Frame: Approximately 12 months ]
  9. Cmax (maximum plasma concentration) of avelumab when given in combination with entinostat [ Time Frame: Pre-dose and post-infusion on Day 1 of Cycles 1 thru 6, then cycles 8, 10, 12, 16, 20, 28, 32, 36, 48, and at the 90-day follow-up (UP TO 24 MONTHS) ]
  10. Tmax (time of maximum plasma concentration) of avelumab when given in combination with entinostat [ Time Frame: Pre-dose and post-infusion on Day 1 of Cycles 1 thru 6, then cycles 8, 10, 12, 16, 20, 28, 32, 36, 48, and at the 90-day follow-up (UP TO 24 MONTHS) ]
  11. Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of avelumab when given in combination with entinostat [ Time Frame: Pre-dose and post-infusion on Day 1 of Cycles 1 thru 6, then cycles 8, 10, 12, 16, 20, 28, 32, 36, 48, and at the 90-day follow-up (UP TO 24 MONTHS) ]
  12. AUC0-inf (area under the plasma concentration-time curve from 0-time extrapolated to infinity) of avelumab when given in combination with entinostat [ Time Frame: Pre-dose and post-infusion on Day 1 of Cycles 1 thru 6, then cycles 8, 10, 12, 16, 20, 28, 32, 36, 48, and at the 90-day follow-up (UP TO 24 MONTHS) ]
  13. t1/2 (elimination half-life and apparent plasma terminal phase elimination rate constant) of avelumab when given in combination with entinostat [ Time Frame: Pre-dose and post-infusion on Day 1 of Cycles 1 thru 6, then cycles 8, 10, 12, 16, 20, 28, 32, 36, 48, and at the 90-day follow-up (UP TO 24 MONTHS) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancer
  • Recurrent or progressive disease on or after initial platinum-based chemotherapy
  • Evidence of measurable disease based on imaging studies within 28 days before the first dose of study drug
  • Previously received at least 3, but no more than 6, lines of therapy including at least 1 course of platinum-based therapy
  • Patient must have acceptable, applicable laboratory requirements
  • Patients may have a history of brain metastasis provided certain protocol criteria are met
  • Experienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade ≤1 (except alopecia or neuropathy)
  • Able to understand and give written informed consent and comply with study procedures.

Exclusion Criteria:

  • Non-epithelial ovarian carcinomas or ovarian tumors with low malignant potential (i.e., borderline tumors)
  • Another known malignancy that is progressing or requires active treatment (excluding adequately treated basal cell carcinoma or cervical intraepithelial neoplasia/cervical carcinoma in situ or melanoma in situ). Prior history of other cancer is allowed, as long as there is no active disease within the prior 5 years.
  • Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment.
  • Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
  • Previously treated with a histone deacetylase inhibitor (i.e., vorinostat, belinostat, romidepsin, panobinostat), PD-1/PD-L1-blocking antibody (i.e., atezolizumab, nivolumab, pembrolizumab), or a cytotoxic T-lymphocyte associated protein-4 (CTLA-4) agent
  • Currently enrolled in (or completed) another investigational drug study within 30 days prior to study drug administration
  • A medical condition that precludes adequate study treatment or increases patient risk

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02915523


Locations
United States, Florida
H. Lee Moffitt Cancer Center and Research
Tampa, Florida, United States, 33612
Florida Cancer Specialist East Region (SCRI Affiliate)
West Palm Beach, Florida, United States, 33401
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Maryland
Greater Baltimore Medical Center
Baltimore, Maryland, United States, 21204
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Missouri
HCA Midwest Health (SCRI Affiliate)
Kansas City, Missouri, United States, 64131
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19107
United States, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37204
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Syndax Pharmaceuticals
Merck KGaA
Pfizer
Investigators
Study Director: Michael Meyers, MD, PhD Syndax Pharmaceuticals, Inc.
Principal Investigator: Ursula Matulonis, MD Dana-Farber Cancer Institute

Responsible Party: Syndax Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02915523     History of Changes
Other Study ID Numbers: SNDX-275-0603
First Posted: September 27, 2016    Key Record Dates
Last Update Posted: July 10, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: An independent data safety monitoring board (DSMB) will be established for the Phase 2 portion of this study to act in an advisory capacity to the Sponsor with respect to safeguarding the interests of trial patients and assessing the safety of the interventions administered during the trial.

Keywords provided by Syndax Pharmaceuticals:
Ovarian Cancer
Histone Deacetylase Inhibitors
Entinostat
Solid tumor
Avelumab
SNDX-275
Ovarian Neoplasms
Ovarian Diseases
Fallopian Tube Cancer
Peritoneal Cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Neoplasms, Glandular and Epithelial
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms by Histologic Type
Fallopian Tube Diseases
Antibodies, Monoclonal
Entinostat
Histone Deacetylase Inhibitors
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action